Treats human immunodeficiency virus (HIV-1) infection. ANDA 216168, held by Annora Pharma. Darunavir.
As of Nov 16, 2026, ANDA 216168 (Darunavir), held by Annora Pharma, was first approved by FDA on Jan 21, 2025, with 0 approved supplements and 0 published complete response letters.
Darunavir tablets, co-administered with ritonavir (darunavir tablets/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older. Darunavir tablets are a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. Darunavir tablets must be co-administered with ritonavir (darunavir tablets/ritonavir) and with other antiretroviral agents.
| Jan 21, 2025 | Original application | Approved | |
| Jan 21, 2025 | Original application | Tentative approval |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters